ROS1 and non-small cell lung carcinoma: Entrectinib has also received FDA and EMA approval for the treatment of ROS1 positive metastatic NSCLC in view of the positive results obtained in this setting of patients in the STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG trials.